Innovating allergy drug delivery with a needle-free alternative
European Pharmaceutical Review
OCTOBER 17, 2024
This decision was granted a couple of weeks following approval by the US and Drug Administration (FDA). Approximately 40 million people in the US experience Type I allergic reactions due to food, venom or insect stings, 4 and the numbers are similar in Europe. What are the main advantages of EURneffy over similar treatments?
Let's personalize your content